ABS Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Arctic Bioscience (OSL: ABS)
›
Arctic Bioscience (OSL: ABS) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 2.530 NOK on 20 November 2026, down 24.5% over 52 weeks. Its 52-week range is 2.050 NOK to 4.200 NOK: the price is 39.8% below the high and 23.4% above the low.
Its market capitalisation is 68.20M NOK.
Arctic Bioscience reports return on equity of -23.6%, an operating margin of -64.6% and revenue up 33.9% year over year.
Its debt exceeds its cash by 80.22M NOK, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.